This case, the outcome on "Parexel International Corporation (A)", describes the events at Parexel and the biopharmaceutical industry from 2002 to 2011. Through the investment of $ 365 million over 10 years, Parexel has strong technology business services, which is its key differentiator, although clinical trials are the most profitable segment. In addition, Parexel, like other industries, has expanded its presence in the cheaper places, especially in the strategically important Asia-Pacific region. Another key change is the growing number of long-term strategic partnership between the OCI and biopharmaceutical customers, reflecting a strong, more equal relationship between the two players. These developments took place against the background of a constant lull in R & D productivity and profitability of grave concern among large pharmaceutical companies, as some of their best selling products face competition from generics. With some observers predict overhaul of biopharmaceutical R & D structure, students are left to consider what the future holds for Parexel. "Hide
by Regina E. Herzlinger, Natalie Kindred Source: Harvard Business School 9 pages. Publication Date: June 30, 2011. Prod. #: 311087-PDF-ENG
Related Case Solutions & Analyses:
Charles Schwab in 2002 Spreadsheet Exercise
Saras Options
Fsas: Fujitsu Support and Service Inc.
Yahoo’s Acquisition of Tumblr
Vic Young and Fishery Products International (B): Winds of Change
Schumpeter Finanzberatung GmbH
Bosch Group in India: Transition to the interpersonal organization
Banff Aspen Lodge: Evolving the Business Strategy
Berkshire Partners: Bidding for Carter’s
Evaluate Cola’s strategy of buying bottlers, making them stronger, and then selling them again. Would you change this strategy? Do you agree with it?
